Literature DB >> 28336290

Serum microRNA Expression Profiling: Potential Diagnostic Implications of a Panel of Serum microRNAs for Clear Cell Renal Cell Cancer.

Siddharth Yadav1, Madhuram Khandelwal2, Amlesh Seth1, Ashish K Saini1, Prem N Dogra1, Alpana Sharma3.   

Abstract

OBJECTIVE: To study the expression profiles of 5 microRNAs in tissue and serum of patients with clear cell renal cell cancer (ccRCC) and evaluate their diagnostic and prognostic potential.
MATERIALS AND METHODS: We prospectively analyzed 30 patients of histologically proven ccRCC and collected 3 mL of serum preoperatively and small pieces of tumor and adjacent non-tumor renal tissue intraoperatively. Control serum samples were obtained from 15 patients of non-renal benign diseases. We analyzed 5 miRNAs-miR-34a, miR-141, miR-200c, miR-1233, and miR-21-2. Freshly collected samples were immediately frozen in liquid nitrogen and total RNA was extracted. cDNA was synthesized by reverse transcription, and quantitative polymerase chain reaction was performed to determine relative miRNA expression.
RESULTS: In the renal tissue and serum samples, 3 out of 5 miRNAs were differentially expressed; that is, the expression levels of miR-34a and miR-141 were significantly decreased, whereas that of miR-1233 was significantly increased. Serum miR-34a, miR-141, and miR-1233 were able to diagnose ccRCC with a sensitivity of 80.76%, 75%, and 93.33%, and specificity of 80%, 73.33%, and 100%, respectively, as compared to histopathology. Using a panel of 2 serum miRNAs (miR-141 and miR-1233) ccRCC can be diagnosed with 100% sensitivity and 73.3% specificity.
CONCLUSION: miRNAs are differentially expressed in serum of patients with ccRCC and can be used to diagnose ccRCC with high sensitivity and specificity. Diagnostic sensitivity can be further improved by using a panel of miRNAs and has the potential to serve as novel diagnostic markers of ccRCC.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28336290     DOI: 10.1016/j.urology.2017.03.013

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  Circ_RPL23A acts as a miR-1233 sponge to suppress the progression of clear cell renal cell carcinoma by promoting ACAT2.

Authors:  Liang Cheng; Huifeng Cao; Jianbo Xu; Mo Xu; Wenjie He; Wenjing Zhang; Longxin Dong; Dayin Chen
Journal:  J Bioenerg Biomembr       Date:  2021-05-25       Impact factor: 2.945

2.  Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder.

Authors:  Pradeep Singh; Aishwarya Singh; Nidhi Gupta; K David Raja; Prabhjot Singh; Sarita Agarwal; Alpana Sharma
Journal:  Mol Cell Biochem       Date:  2022-04-20       Impact factor: 3.842

3.  Circular RNA hsa-circ-0007766 modulates the progression of Gastric Carcinoma via miR-1233-3p/GDF15 axis.

Authors:  Weiguo Xu; Bin Zhou; Jun Wu; Pan Jiang; Huanqiu Chen; Feng Yan
Journal:  Int J Med Sci       Date:  2020-06-23       Impact factor: 3.738

Review 4.  MicroRNA Signature in Renal Cell Carcinoma.

Authors:  Soudeh Ghafouri-Fard; Zeinab Shirvani-Farsani; Wojciech Branicki; Mohammad Taheri
Journal:  Front Oncol       Date:  2020-11-30       Impact factor: 6.244

5.  Systematic Analysis of microRNA Biomarkers for Diagnosis, Prognosis, and Therapy in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Guiyun Cheng; Mengru Li; Xiaoyu Ma; Fangmei Nan; Lu Zhang; Zhongyi Yan; Huimin Li; Guosen Zhang; Yali Han; Longxiang Xie; Xiangqian Guo
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

6.  LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma.

Authors:  José Pedro Sequeira; Vera Constâncio; Sofia Salta; João Lobo; Daniela Barros-Silva; Carina Carvalho-Maia; Jéssica Rodrigues; Isaac Braga; Rui Henrique; Carmen Jerónimo
Journal:  Cancers (Basel)       Date:  2022-02-09       Impact factor: 6.639

Review 7.  The role of miR-200 family in the regulation of hallmarks of cancer.

Authors:  Klaudia Klicka; Tomasz M Grzywa; Aleksandra Mielniczuk; Alicja Klinke; Paweł K Włodarski
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

Review 8.  Circulating RNA in Kidney Cancer: What We Know and What We Still Suppose.

Authors:  Alessandra Cinque; Riccardo Vago; Francesco Trevisani
Journal:  Genes (Basel)       Date:  2021-05-28       Impact factor: 4.096

9.  Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors.

Authors:  Eman A Toraih; Saleh Ali Alghamdi; Aya El-Wazir; Marwa M Hosny; Mohammad H Hussein; Moataz S Khashana; Manal S Fawzy
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.240

Review 10.  Potential clinical applications of microRNAs as biomarkers for renal cell carcinoma.

Authors:  Yulian Mytsyk; Victor Dosenko; Michał Andrzej Skrzypczyk; Yuriy Borys; Yuriy Diychuk; Askold Kucher; Vasyl Kowalskyy; Serhyi Pasichnyk; Oleh Mytsyk; Lubov Manyuk
Journal:  Cent European J Urol       Date:  2018-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.